Chemical Week Magazine :: Pharmaceuticals & Fine Chemicals
Sandoz Gains Biosimilar Approval
9:58 AM MDT | July 10, 2009
Sandoz (Holzkirchen, Germany), a division of Novartis, says it has received marketing authorization for the first ever biosimilar to be sold in Japan. Approval of the product, recombinant human growth hormone somatropin, paves the way for greater market access for high-quality biopharmaceuticals in Japan, Sandoz says. Japan is the second-largest pharmaceuticals market after the U.S. Biosimilars are approved versions of innovator biopharmaceutical products, following patent expiry. The Sandoz product is approved for the treatment of growth hormone deficiency in...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee